The UltraCon™ Ultrafiltrator is indicated for use as an ultrafiltrator for the selective removal of undesireable plasma water and small dissolved solutes from blood plasma proteins and formed cellular elements, as may be present in cases of acute hemodilution such as following cardiopulmonary bypass.

Device Description

The Ultracon™ Ultrafiltrator is constructed of semipermeable hollow fibers, which divide the device into two compartments. An inner pathway for diluted blood perfusate is defined by the inlet and outlet connectors and flow dispersion headers, which are connected through the inner lumen of semipermeable hollow fiber membranes. Surrounding the hollow fibers is an enclosed, vented compartment for the collection of ultrafiltrate waste water.

When dilute blood or a blood component is allowed to pass through the perfusate pathway, the device acts as an ultrafilter, removing a percentage of the plasma water and small solutes from the perfusate. When perfusate fluid passes through the inner diameter of the hollow fibers, water and small dissolved solutes can pass through the semipermeable membrane walls into the annular ultrafiltrate compartment, to then be discarded. This results in the concentration of formed elements and proteins as they pass along the perfusate pathway.

The UltraCon™ Ultrafiltrator is built with dry cellulose diacetate membranes, a unique material which has been shown to have a high level of biocompatibility. The absence of any bore fluid provides the convenience of using the device without the need for rinsing. Each device is supplied in a sealed plastic and foil package, to maintain a sterile, non-pyrogenic perfusate pathway.

Although constructed of highly permeable membrane material, the low total membrane surface area of the UltraCon™ Ultrafiltrator inherently limits the maximum rate of water removal. Neither an ultrafiltration rate monitor nor a controller is necessary. Average ultrafiltration rate will vary directly according to perfusate flow rate, transmembrane pressure, or temperature, and inversely according to its protein concentration and hematocrit.

AI/ML Overview

The provided document is a 510(k) Summary for the UltraCon™ Ultrafiltrator, dated February 24, 1998. It primarily focuses on demonstrating substantial equivalence to predicate devices, rather than presenting a detailed study with specific acceptance criteria and performance data in the format requested.

Therefore, much of the requested information, such as detailed acceptance criteria, specific performance metrics from a study against those criteria, sample sizes for test and training sets, expert qualifications, adjudication methods, and MRMC study details, is not present in the provided document.

However, based on the information available, I can extract and infer the following:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly present a table of acceptance criteria linked to a study's performance results. Instead, it lists "UltraCon™ Ultrafiltrator Specifications" which serve as design specifications and implicitly, as targets for acceptable performance. The comparison to predicate devices also implies that performance similar to these predicates would be acceptable.

Acceptance Criteria (Implied from Specifications)	Reported Device Performance (Implied from Specifications)
Overall unit length, cm: 15	15 cm
Effective fiber length, cm: 11	11 cm
Unit diameter, cm: 1.8	1.8 cm
Membrane area, nominal M²: 0.11	0.11 M²
Perfusate flow resistance, nominal, mm Hg/ml/min: 0.15	0.15 mm Hg/ml/min
Maximum allowable transmembrane pressure (TMP), mm Hg: 500	500 mm Hg
Priming volume, ml: 5	5 ml
Residual volume, ml: 1	1 ml
Hemo-concentration (kUF) typical rate, ml/hr/mm Hg: 1	1 ml/hr/mm Hg
Molecular weight nominal cutoff, Daltons: < 65,000	< 65,000 Daltons

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not present in the provided 510(k) Summary. 510(k) summaries typically focus on substantial equivalence based on design, materials, and intended use, often without detailed clinical study data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not present. The document doesn't describe a ground truth establishment process for a test set.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not present.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This is not applicable as the device (UltraCon™ Ultrafiltrator) is a medical device for ultrafiltration, not an AI-assisted diagnostic tool involving human readers.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This is not applicable for the type of device described.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

This information is not present. The document relies on engineering specifications and comparison to predicate devices. For this type of device, "ground truth" would likely refer to physical measurements of its performance characteristics (e.g., actual ultrafiltration rate, pressure limits, molecular weight cutoff) under controlled laboratory conditions, rather than clinical outcomes or expert consensus on diagnostic images.

8. The sample size for the training set

This information is not present.

9. How the ground truth for the training set was established

This information is not present.

Summary of what the document does provide regarding device performance and acceptance:

The document primarily demonstrates substantial equivalence by showing that the "Product design, materials of construction, and function as an ultrafiltrator are substantially equivalent to FDA cleared predicate devices." The listed specifications for the UltraCon™ Ultrafiltrator define its intended performance parameters, which are implicitly accepted as meeting the required standards because they are comparable to established predicate devices (Altra FLUX™ 140 Hemodialyzer, Minifilter™ Hemofilter, Hemocor HPHTM 400 Hemoconcentrator). The acceptance criteria are therefore largely based on matching or being within acceptable ranges of these established specifications and the similar performance characteristics of the predicate devices.

Summary

{0}------------------------------------------------

・・

1971710

FEB < 7 1998

510(k) SUMMARY

SUBMITTED BY:

Andrew G. Hood President Quantic Biomedical, Inc. 810 "E" Street San Rafael, CA 94901-2819 USA

Primary Phone:	415-365-0995
Primary Fax:	415-365-0522
Alternate Phone:	415-453-1008
Alternate Fax:	415-457-0278

February 24, 1998 Date Submitted:

CLASSIFICATION, COMMON OR USUAL NAME, DEVICE NAME

Classification Name: Conventional Hemodialyzer, under 21 CFR 876.5820

Common or Usual Name:	Ultrafiltrator
Proprietary Name:	UltraCon™ Ultrafiltrator

PREDICATE DEVICES

Predicate Device 1;	Altra FLUX™ 140 Hemodialyzer,Althin Medical, Inc.Reference Number K945620/A.
Predicate Device 2;	Minifilter™ Hemofilter,Amicon Division, WR Grace & Co.Reference Number unknown.
Predicate Device 3;	Hemocor HPHTM 400 HemoconcentratorMinntech Corporation.Reference Number unknown.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the number 3012319545, followed by a colon and a hashtag. The image also contains the identifier K971710. The text "Page 2/3" is also present in the image.

INDICATIONS

The UltraCon™ Ultrafiltrator is indicated for use as an ultrafiltrator for the selective removal The Onacon - Ontaintation is mail dissolved solutes from blood plasma proteins and formed cellular elements, as may be present in cases of acute hemocillution such as following cardiopulmonary bypass.

DEVICE DESCRIPTION

UltraCon™ Ultrafiltrator Specifications

Overall unit length, cm	15
Effective fiber length, cm	11
Unit diameter, cm	1.8
Membrane area, nominal M²	0.11
Perfusate flow resistance, nominal, mm Hg/ml/min	0.15
Maximum allowable transmembrane pressure (TMP), mm Hg	500
Priming volume, ml	5
Residual volume, ml	1
Hemo-concentration (kUF) typical rate, ml/hr/mm Hg	1
Molecular weight nominal cutoff, Daltons	< 65,000

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the text '3012319545;# 6/ 6' at the top. Below that, the text 'Page. 3/3' is visible. At the bottom left, the text 'K971710' is present. The text appears to be part of a document or form, possibly indicating a page number or identification code.

CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND COMPLICATIONS

While there are no known absolute contraindications to ultrafiltration therapy, maintenance of blood outside the body requires administration of anticoagulants and other medications to the patient or the collected blood. All drugs and medications should be closely monitored by the orescribing physician to detect any alteration in their effective concentration due to the ultrafiltration process. Because the clearance of some drugs may be variable, the directions and contraindications for use must be in keeping with the patient's medical history and status.

The UltraCon™ Ultrafiltrator is contraindicated for use with direct patient connection. Use as a dialyzer, or for any dialysis procedure, is also contraindicated.

The UltraCon™ Ultrafiltrator is intended for use solely by a physician, or under the direction of a physician by qualified personnel who understand its operation, and by prescription only. It is intended for single patient, single procedure use only, and should not be resterilized or reused.

The UltraCon™ Ultrafiltrator is sterilized by gamma irradiation. The blood pathway is sterile and nonpyrogenic in an unopened, undamaged package. The product should not be used if the protective package is damaged or if the perfusate port caps are missing. Aseptic technique is required to avoid contamination of the perfusate pathway when making connections.

During set up and priming, a leak test should be conducted to detect perfusate pathway leaks. During use, the filtrate should be carefully monitored for the appearance of blood, indicating a leak within the device. If red cells appear in the filtrate during use, a fiber rupture has occurred and the leaking device should be replaced with a new device. Perfusate flow rates should not exceed 60 ml/min and transmembrane pressures must not exceed 500 mm Hg. A vacuum regulator should be used if vacuum suction is desired for increased fluid removal rates. Rapid alterations of flow or transmembrane pressure may cause leakage. Perfusate flow and filtrate vacuum settings should be increased or decreased gradually.

The UltraCon™ Ultrafiltrator is made with a highly permeable membrane. Ultrafiltration will occur if the filtrate line is unclamped, even without applied vacuum. If no ultrafiltration is required, the filtrate line should be clamped. The high permeability of this ultrafilter allows high concentration levels to be achieved. Perfusate concentration to a hematocrit greater than 50% should be avoided. A minimum perfusate flow rate of 15 ml/min through the ultrafiltrator should be maintained at all times to prevent plugging of membrane channels or clotting. During use, the filtrate collection chamber must be positioned below the ultrafiltrator to prevent back filtration.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS

Product design, materials of construction, and function as an ultrafiltrator are substantially equivalent to FDA cleared predicate devices.

{3}------------------------------------------------

Image /page/3/Picture/2 description: The image shows a logo for the Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN" around the left side of the circle. The right side of the circle is blank. Inside the circle is a symbol that looks like a stylized human figure.

FEB 2 7 1998

Quantic Biomedical, Inc. c/o Glenn N. Byrd. MBA Associate Director of Regulatory Affairs Advanced Bioresearch Associates 1700 Rockville Pike, Suite 450 Rockville, MD 20852

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Re: K971710 UltraCon™ Ultrafiltrator Dated: February 24, 1998 Received: February 25, 1998 Regulatory Class: II 21 CFR 876.5820/Procode: 78 FJI

Dear Mr. Byrd:

We have reviewed vour Section 5100) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Feleral Food, Drug, and Councile Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Feleval Regulations, Title 21. Parts 800 to 895. A substantially equivalience compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Rogulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (S inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 542 of the Act for derices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predication for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for intro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdr/dsmaldsmamain.html".

Sincerely yours,

Lillian Yin, Ph.D.

Director, Division of Reproducti Abdominal, Ear, Nose and Throat and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Reference 510(k) K971710, Supplement page 4, 9/11/97

INDICATIONS FOR USE 3)

510(k) Number: K971710

UltraCon™ Ultrafiltrator Device Name:

Indications for Use:

: 1

y bypass.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrance of CDRH, Office of Device Evaluation (ODE)

	Daber D alling /
	(Division Sign-Off)
	Division of Reproductive, Abdominal, ENT, and Radiological Devices
Prescription Use	510(k) Number K971710
(Per 21 CFR 801.109)

Over-the-Counter Use_

Prescription Use, by or on the order of a physician (PER 21 CFR 801.109)

(Optional Format 1-2-96)

Regulation Number and Section

§ 876.5820 Hemodialysis system and accessories.

(a)
Identification. A hemodialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and that consists of an extracorporeal blood system, a conventional dialyzer, a dialysate delivery system, and accessories. Blood from a patient flows through the tubing of the extracorporeal blood system and accessories to the blood compartment of the dialyzer, then returns through further tubing of the extracorporeal blood system to the patient. The dialyzer has two compartments that are separated by a semipermeable membrane. While the blood is in the blood compartment, undesirable substances in the blood pass through the semipermeable membrane into the dialysate in the dialysate compartment. The dialysate delivery system controls and monitors the dialysate circulating through the dialysate compartment of the dialyzer.(1) The extracorporeal blood system and accessories consists of tubing, pumps, pressure monitors, air foam or bubble detectors, and alarms to keep blood moving safely from the blood access device and accessories for hemodialysis (§ 876.5540) to the blood compartment of the dialyzer and back to the patient.
(2) The conventional dialyzer allows a transfer of water and solutes between the blood and the dialysate through the semipermeable membrane. The semipermeable membrane of the conventional dialyzer has a sufficiently low permeability to water that an ultrafiltration controller is not required to prevent excessive loss of water from the patient's blood. This conventional dialyzer does not include hemodialyzers with the disposable inserts (Kiil type) (§ 876.5830) or dialyzers of high permeability (§ 876.5860).
(3) The dialysate delivery system consists of mechanisms that monitor and control the temperature, conductivity, flow rate, and pressure of the dialysate and circulates dialysate through the dialysate compartment of the dialyzer. The dialysate delivery system includes the dialysate concentrate for hemodialysis (liquid or powder) and alarms to indicate abnormal dialysate conditions. This dialysate delivery system does not include the sorbent regenerated dialysate delivery system for hemodialysis (§ 876.5600), the dialysate delivery system of the peritoneal dialysis system and accessories (§ 876.5630), or the controlled dialysate delivery system of the high permeability hemodialysis system § 876.5860).
(4) Remote accessories to the hemodialysis system include the unpowered dialysis chair without a scale, the powered dialysis chair without a scale, the dialyzer holder set, dialysis tie gun and ties, and hemodialysis start/stop tray.
(b)
Classification. (1) Class II (performance standards) for hemodialysis systems and all accessories directly associated with the extracorporeal blood system and the dialysate delivery system.(2) Class I for other accessories of the hemodialysis system remote from the extracorporeal blood system and the dialysate delivery system, such as the unpowered dialysis chair, hemodialysis start/stop tray, dialyzer holder set, and dialysis tie gun and ties. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.